Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neurontin, Paxil Generic Exclusivity Disputes Dismissed By Appeals Court

This article was originally published in The Pink Sheet Daily

Executive Summary

The appellate judges decline to rule on the validity of FDA’s patent-by-patent approach to awarding generic marketing exclusivity in either case. Apotex’ challenge to Purepac’s gabapentin exclusivity is barred by earlier litigation, court says; FDA’s appeal stemming from paroxetine exclusivity ruling is dismissed as moot.

You may also be interested in...



Barr Is Latest Generic Firm To Challenge FDA’s Patent-Based Exclusivity Policy

In a D.C. federal court lawsuit, Barr asserts it was the first applicant to file a Paragraph IV certification against any “Orange Book” listed patent for Allegra-D. Consequently, the company says, it should not have to share 180-day generic marketing rights with Impax.

Barr Is Latest Generic Firm To Challenge FDA’s Patent-Based Exclusivity Policy

In a D.C. federal court lawsuit, Barr asserts it was the first applicant to file a Paragraph IV certification against any “Orange Book” listed patent for Allegra-D. Consequently, the company says, it should not have to share 180-day generic marketing rights with Impax.

FDA's Patent-Based ANDA Exclusivity Policy Challenged By Apotex

Apotex files suit to force approval of its Prilosec ANDA, which is being held up by Andrx' exclusivity. Suit charges that FDA improperly granted Andrx additional period of exclusivity for omeprazole 40 mg based on a late-filed patent.

Related Content

Topics

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel